NURS5205 Pharmacotherapeutics for Nursing
The Complete Exam Bible · Semester 2 2026NURS5205 Overview
- University of Sydney
- Semester 2 2026
- 10 chapters
- Nursing
NURS5205 Pharmacotherapeutics for Nursing is a postgraduate University of Sydney unit that develops safe, patient-specific reasoning about medicine use.
- Assessed by Assessment 1: Quiz 1 25% · Assessment 2: Quiz 2 25% + 1 more
- Key terms Quality use of medicines, Pharmacokinetics, Pharmacodynamics, Clearance
- How to prepare Revise by clinical decision rather than by slide order.
- Most asked What is the final exam format?
How NURS5205 is assessed
| Component | Weight | Format |
|---|---|---|
| Assessment 1: Quiz 1 | 25% | 21 August 2026 at 14:00 in the Week 3 tutorial, 25 minutes, closed book, multiple choice, matching and short answer |
| Assessment 2: Quiz 2 | 25% | 18 September 2026 at 14:00 in the Week 7 tutorial, 25 minutes, closed book, multiple choice, matching and short answer |
| Assessment 3: Final Exam Case Based Short Answers Matching Questions | 50% | Formal exam period, 80 minutes, closed book, two case studies with short answers and matching |
Current NURS5205 dates
| Date | Item | Control |
|---|---|---|
| 21 August 2026 at 14:00 | Assessment 1: Quiz 1 | Week 3 tutorial, 25% and 25 minutes. |
| 18 September 2026 at 14:00 | Assessment 2: Quiz 2 | Week 7 tutorial, 25% and 25 minutes. |
Dates are as published in University of Sydney 2026 unit outline. Confirm exact deadlines and submission settings in the live LMS.
What NURS5205 covers
The unit moves from quality use of medicines and core pharmacology into diabetes, cardiovascular, renal, respiratory and gastrointestinal pharmacotherapy, then integrates those systems through case-based reasoning.
Quality Use of Medicines and Medication Safety
Selection, five rights, monitoring, incidents and nursing responsibilityQuality use of medicines starts before administration. This chapter links wise selection, patient-specific suitability, safe and effective use, the five rights, nursing monitoring, adherence support and learning from incidents.
- Quality use of medicines principles
- Nursing roles across medicine use
- Five rights of administration
- Medication incidents and near misses
- Monitoring benefit and harm
- Patient communication and adherence
Pharmacokinetics and Pharmacodynamics
ADME, clearance, distribution, half-life, targets and variable responsePharmacokinetics explains absorption, distribution, metabolism and excretion, while pharmacodynamics explains targets, effects and response.
- ADME and routes of administration
- Clearance and dose rate
- Volume of distribution and loading dose
- Bioavailability and route conversion
- Half-life and dosing frequency
- Targets, agonists and antagonists
Diabetes Pharmacotherapy
Individual treatment, glucose safety, escalation and whole-person monitoringDiabetes pharmacotherapy joins glucose management to diet, activity, blood pressure, lipids, acute complications and progressive disease. The chapter focuses on patient-specific medicine selection, predictable adverse effects, precautions and monitoring.
- Diabetes pathophysiology and presentation
- Individual treatment goals
- Glucose-lowering medicine roles
- Hypoglycaemia recognition and response
- Cardiovascular and renal context
- Monitoring and treatment escalation
Cardiovascular Risk and Hypertension
Risk estimation, measurement, treatment selection and surveillanceCardiovascular risk tools estimate probability and inform prevention, but they are not certain predictions and do not fit every patient.
- Purpose of cardiovascular risk assessment
- Calculator limitations and exceptions
- Blood pressure measurement quality
- Hypertension pathophysiology and consequences
- Antihypertensive medicine roles
- Postural effects and ongoing monitoring
Dyslipidaemia, Coronary Disease and ACS
Prevention, acute coronary priorities and secondary preventionThis chapter uses a timeline to separate long-term lipid and coronary prevention, time-critical acute coronary syndrome care and secondary prevention after an event.
- Dyslipidaemia and cardiovascular risk
- Coronary disease pathophysiology
- Acute coronary syndrome recognition
- Immediate treatment goals
- Bleeding and haemodynamic monitoring
- Post-event secondary prevention
Heart Failure and Atrial Fibrillation
Congestion, rate or rhythm, stroke prevention and monitoringHeart failure and atrial fibrillation frequently coexist but represent different therapeutic problems. Heart failure reasoning centres on cardiac function, congestion, disease modification and fluid-related monitoring.
- Heart failure presentation and phenotype
- Congestion and treatment goals
- Disease-modifying and symptom roles
- Atrial fibrillation presentation
- Rate control and rhythm control
- Stroke risk and anticoagulation
Kidney Function, Injury and Chronic Disease
Estimation, medicine dosing, acute injury, chronic disease and escalationKidney-function estimates support disease tracking and medicine dosing, but each result must be interpreted with patient size, stability, disease trajectory and medicine-specific handling.
- eGFR and kidney-function estimation
- Estimate limitations and body size
- Renal medicine elimination
- Acute kidney injury and instability
- Severe hyperkalaemia escalation
- Chronic kidney disease progression
Asthma and COPD Pharmacotherapy
Comparative disease control, inhaler roles, technique and reviewAsthma and COPD are different diseases that may use similar medicine classes and inhaler devices.
- Asthma and COPD comparison
- Airflow limitation and clinical pattern
- Controller and reliever roles
- Bronchodilator treatment goals
- Inhaler device technique
- Symptoms, exacerbations and review
GORD and Peptic Ulcer Pharmacotherapy
Reflux, ulcer causes, acid suppression, eradication and bleeding riskUpper gastrointestinal symptoms can overlap, but GORD and peptic ulcer disease require different causal reasoning. This chapter connects reflux pathophysiology to lifestyle and acid suppression, then separates H.
- GORD presentation and risk factors
- Reflux pathophysiology
- Non-drug and acid-suppressing therapy
- Peptic ulcer mechanisms
- H. pylori eradication
- NSAID-associated ulcer risk
Integrated Case Reasoning for the Final
Two case studies, short answers, matching and time managementThe published final contains two 25-mark case studies, six to seven questions in each case, short answers and matching, with 80 minutes writing and 10 minutes reading.
- Reading-time case mapping
- Drug recognition and matching
- Short-answer causal links
- Patient-specific risk factors
- Numerical work with units
- Time allocation by marks
The teaching begins with quality use of medicines, medication safety, pharmacokinetics and pharmacodynamics, then applies those foundations to diabetes, cardiovascular disease, kidney disease, asthma, chronic obstructive pulmonary disease, gastro-oesophageal reflux and peptic ulcer disease. The unit materials describe it as challenging and application-focused.
That challenge is visible in the cases: a useful answer must connect a medicine to the treatment goal and mechanism, then explain how kidney function, age, comorbidity, interactions, adherence, route or disease progression can alter exposure and response. Nursing action remains central throughout.
Students are expected to recognise safe administration requirements, monitor benefit and harm, support medicine use, communicate changes and escalate urgent findings. The assessment structure reinforces this approach. Two closed-book tutorial quizzes each contribute 25 percent, and a closed-book supervised final contributes 50 percent. The final uses case-based short answers, drug recognition or matching and two case studies.
This guide therefore organises revision around a recurring chain: identify the clinical problem, state the treatment goal, connect mechanism and medicine, test the choice against patient-specific risk, name monitoring, and finish with the nursing action. Numerical relationships are shown with units and interpretation, while treatment decisions remain grounded in authorised guidance and clinical review.
The result is not a substitute for current local policy or prescribing information. It is a structured way to retrieve the pharmacology and explain why it matters for the patient in front of you.
Worked example · free
Explaining why acute illness changes medicine risk
- +1This mark allocation is not a University marking scheme. Assess immediate stability, observations, glucose and neurological change.
- +1Compare kidney function and fluid status with the patient's baseline and timeline.
- +1Reconcile recent doses and identify medicines dependent on renal elimination or haemodynamic tolerance.
- +1Escalate promptly for authorised medicine review rather than calculating a new regimen from one estimate.
- +1Document trends, actions and the response to the revised care plan.
Key terms
- Quality use of medicines
- Selecting management options wisely, choosing suitable medicines when needed, and using medicines safely and effectively.
- Pharmacokinetics
- How the body handles a drug through absorption, distribution, metabolism and excretion.
- Pharmacodynamics
- How a drug acts on the body through targets, effects and clinical response.
- Clearance
- A measure of elimination efficiency that helps determine dose rate.
- Volume of distribution
- The apparent extent of drug distribution that helps determine a loading dose.
- Bioavailability
- The fraction of an administered dose that reaches systemic circulation.
- Half-life
- The time describing how long a drug or metabolite remains in the body, shaped by clearance and distribution.
- Cardiovascular risk
- An estimate of future cardiovascular disease probability used to inform prevention, not a certain prediction.
- Acute kidney injury
- A rapid change in kidney function that can make medicine exposure unstable and require urgent review.
- Chronic kidney disease
- Persistent kidney abnormality managed by slowing progression, treating complications and reviewing medicine use.
- Rate control
- Atrial fibrillation treatment aimed at controlling ventricular rate rather than restoring rhythm.
- Eradication therapy
- A complete prescribed regimen intended to remove H. pylori rather than only suppress ulcer symptoms.
NURS5205 FAQ
How hard is this pharmacotherapeutics unit?
The lecturer describes the unit as challenging, rewarding and focused on application. The main workload comes from linking many medicine classes to mechanism, patient factors, adverse effects, precautions, monitoring and nursing action. A steady case-based revision routine is more useful than memorising isolated lists near the final.
How is the unit assessed?
There are two closed-book tutorial quizzes worth 25 percent each and a supervised closed-book final worth 50 percent. The quizzes mix multiple choice, matching and short answer. The final uses case-based short answers, drug recognition or matching and two case studies.
What is the final exam format?
The exam-preparation material states 80 minutes of writing plus 10 minutes reading time. It contains two case studies worth 25 marks each, with six to seven questions in each case. The content range runs from Week -1 through Week 10.
What content is covered in each quiz?
Quiz 1 covers lecture, tutorial and reading content from Week -1 through Week 2. Quiz 2 covers Weeks 3 through 6. Both are held in the scheduled tutorial, last 25 minutes and are closed book.
How should I revise clinical cases?
Use one repeatable chain: identify the problem, state the treatment goal, connect the medicine and mechanism, test the choice against patient-specific risks, name benefit and harm monitoring, and finish with the nursing action or escalation. Practise retrieving that chain under time pressure.
Are past papers available in these materials?
The captured materials include an exam-format slide but no past final paper, sample final or final-exam solution. Use the published item types and tutorial reasoning patterns for practice, but treat every practice scenario in this guide as newly authored rather than a prediction of the actual paper.
Questions students ask in each NURS5205 chapter
- Why are the five rights not the whole safety answer?
- They test administration accuracy, but quality use also asks whether the medicine is needed, suitable, effective and causing harm. A complete response uses the current patient assessment, indication, monitoring plan and local escalation pathway alongside the five checks. Chapter 01 · Quality Use of Medicines and Medication Safety
- What is the quickest way to separate PK from PD?
- Ask whether the statement concerns drug concentration or the body's response to that concentration. Absorption, clearance and metabolism are pharmacokinetic. Receptor sensitivity, agonism, antagonism and the magnitude of effect are pharmacodynamic. Chapter 02 · Pharmacokinetics and Pharmacodynamics
- Why is diabetes management broader than lowering glucose?
- The teaching material integrates diet, exercise, glucose, blood pressure and lipids because diabetes outcomes depend on more than one laboratory measure. Medicine benefit must be balanced against acute harm, chronic complications, feasibility and cardiovascular or renal risk. Chapter 03 · Diabetes Pharmacotherapy
- Why is a cardiovascular risk score not a prediction?
- It estimates probability from population evidence. A high-risk person may not have an event, and a low-risk person still can. Use the estimate to support prevention decisions while explaining uncertainty, eligibility limits and possible treatment harms. Chapter 04 · Cardiovascular Risk and Hypertension
- Why should dyslipidaemia not be treated as an isolated number?
- Lipid results sit inside total cardiovascular risk and established disease status. Medicine benefit, intensity and monitoring depend on the patient's broader risk, comorbidity, adverse-effect profile and ability to continue therapy. Chapter 05 · Dyslipidaemia, Coronary Disease and ACS
- Why should heart failure and AF be separated in an answer?
- They have different immediate questions. Heart failure asks about congestion, function and disease-modifying therapy. AF asks about stability, rate or rhythm and stroke prevention. Integration is important, but combining them too early hides treatment purpose and monitoring. Chapter 06 · Heart Failure and Atrial Fibrillation
- Why is eGFR useful but not sufficient for dosing?
- It estimates kidney function and is adequate for many decisions, but stability, body size, medicine-specific evidence, acute illness and clinical context can alter interpretation. Some cases require an absolute rather than indexed estimate or another dosing approach. Chapter 07 · Kidney Function, Injury and Chronic Disease
- Why can similar inhalers mean different things in asthma and COPD?
- The diseases have different pathophysiology, patterns and treatment priorities. A shared bronchodilator or device does not create an identical plan. State the medicine role, disease goal, review criteria and patient context for the condition in the case. Chapter 08 · Asthma and COPD Pharmacotherapy
- Why is acid suppression not the whole ulcer answer?
- It can relieve symptoms and support healing, but ulcer management also asks about H. pylori, NSAID exposure, bleeding, adherence and the ongoing need for the causative medicine. Symptom relief alone does not establish eradication or exclude harm. Chapter 09 · GORD and Peptic Ulcer Pharmacotherapy
- What should I do during the 10 minutes reading time?
- Label each case by body system, urgent issue, medicines, comorbidities and changed observations. Scan every subquestion because later data may clarify the story. Mark the command verb and plan time before writing a detailed response. Chapter 10 · Integrated Case Reasoning for the Final
How to study for the exam
Revise by clinical decision rather than by slide order. For every medicine class, make a compact card with the treatment goal, target or mechanism, expected benefit, important harms, precautions, patient factors that alter exposure, and the observations that support continuation or escalation. Then apply the card to a short case and force each sentence to use a patient fact.
Keep pharmacokinetics and pharmacodynamics distinct: renal clearance, absorption and interactions change exposure, while receptor sensitivity and disease state change response. For each body-system block, compare nearby conditions so shared medicines do not erase different goals. In the final week, complete timed two-case sets. Use reading time to label body system, urgency, medicines, comorbidities and changed observations.
Answer with claim, because, therefore, monitor. Recompute numerical examples with units, and never let a precise result replace clinical judgement. Finish each session by retrieving safety triggers such as possible bleeding, severe respiratory distress, acute neurological change or dangerous electrolyte disturbance, because urgent recognition should come before a polished discussion of long-term therapy.
Your AI Nursing tutor for NURS5205
Stuck on a hard NURS5205 question? Sia is AskSia’s AI Nursing tutor — ask any NURS5205 Pharmacotherapeutics for Nursing question and get a clear, step-by-step explanation grounded in how the course is actually taught and assessed. Read this whole study guide free, then take your hardest questions to Sia.
